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ABSTRACT
Objective: Arm exercise stress testing may be an
equivalent or better predictor of mortality outcome
than pharmacological stress imaging for the ≥50% for
patients unable to perform leg exercise. Thus, our
objective was to develop an arm exercise ECG stress
test scoring system, analogous to the Duke Treadmill
Score, for predicting outcome in these individuals.
Methods: In this retrospective observational cohort
study, arm exercise ECG stress tests were performed in
443 consecutive veterans aged 64.1 (11.1) years.
(mean (SD)) between 1997 and 2002. From
multivariate Cox models, arm exercise scores were
developed for prediction of 5-year and 12-year allcause and cardiovascular mortality and 5-year
cardiovascular mortality or myocardial infarction (MI).
Results: Arm exercise capacity in resting metabolic
equivalents (METs), 1 min heart rate recovery (HRR)
and ST segment depression ≥1 mm were the stress
test variables independently associated with all-cause
and cardiovascular mortality by step-wise Cox analysis
(all p<0.01). A score based on the relation HRR (bpm)
+7.3×METs−10.5×ST depression (0=no; 1=yes)
prognosticated 5-year cardiovascular mortality with a
C-statistic of 0.81 before and 0.88 after adjustment for
significant demographic and clinical covariates. Arm
exercise scores for the other outcome end points
yielded C-statistic values of 0.77–0.79 before and
0.82–0.86 after adjustment for significant covariates
versus 0.64–0.72 for best fit pharmacological
myocardial perfusion imaging models in a cohort of
1730 veterans who were evaluated over the same time
period.
Conclusions: Arm exercise scores, analogous to the
Duke Treadmill Score, have good power for prediction
of mortality or MI in patients who cannot perform leg
exercise.

INTRODUCTION
The Duke Treadmill Score has been well validated and widely used for many years as a
powerful prognostic marker in patients being
evaluated for coronary artery disease.1–3
However, in recent years at least 50% of
patients referred for stress testing are unable
to perform adequate treadmill exercise
because of lower extremity or other disabilities and pharmacological evaluations are

KEY QUESTIONS
What is already known about this subject?
▸ No scoring system exists for outcome prediction
from arm exercise stress test results in the
≥50% of patients unable to perform leg exercise.

What does this study add?
▸ We developed a scoring system, analogous to
the Duke Treadmill Score, for arm exercise
stress testing.

How might this impact on clinical practice?
▸ With this scoring system, 5-year and 12-year allcause and cardiovascular mortality or myocardial
infarction can be estimated from easily measured
arm exercise stress test variables with comparable accuracy to the Duke Treadmill Score in
patients unable to perform leg exercise.

employed as a surrogate form of stress,4 for
which the Duke Treadmill Score is not relevant. In addition, the Duke Treadmill Score
does not include variables such as heart rate
recovery that have been found to be highly
predictive of mortality.5 6 Although pharmacological stress tests may yield useful imaging
results, they fail to provide powerful prognostic information on exercise capacity, symptomatic, physiological or ECG responses to
the relevant physiological stress of exercise.
We have demonstrated that arm exercise
stress testing is at least equivalent and possibly
a superior alternative to pharmacological evaluations7 in patients unable to perform leg
exercise and is predictive of all-cause and cardiovascular mortality over 5 and 12 years7–9
and myocardial infarction (MI) at 5 years.10
However, a simple scoring system, analogous
to the Duke Treadmill Score, is not currently
available for arm exercise testing. Thus, the
purpose of this investigation was to develop
and report a simple scoring system for predicting outcome, deﬁned in terms of 5-year
and 12-year all-cause mortality, 5-year and
12-year cardiovascular mortality, and 5-year
cardiovascular mortality or MI for arm exercise ECG stress testing.
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METHODS
Patient characteristics and covariate information
The arm exercise scores were derived from a patient
population of 443 consecutive individuals (434 men, 9
women) aged 64.1 (11.1) years (mean (SD)) who
underwent arm ergometer exercise stress tests at the
St. Louis Veterans Administration Medical Center (STL
VAMC) from 1997 until 2002 and were described in an
earlier publication.7 Veterans who were referred by their
VA healthcare providers, were unable to perform treadmill or leg cycle ergometer exercise because of lower
extremity or other disabilities, and who underwent arm
exercise testing, were eligible for the study. Those
having upper extremity disabilities or medical contraindications to stress testing, identiﬁed in a brief history
and physical examination, were excluded. In <3% of
tests, arm exercise testing was substituted for pharmacological (dipyridamole) evaluations because of caffeinated beverage ingestion and a long travel distance to
St. Louis. Arm exercise studies were converted to
pharmacological evaluations in <2% of participants
because of inability to exercise for at least 1 min.
Participants were instructed to fast overnight, withhold
β-adrenergic blocking agents, administer ½ of their
usual insulin dose, and take all other regular medications. The study was approved by the Institutional
Review Board of the STL VAMC. All patients provided
voluntary written informed consent.
Arm exercise protocol
The stress test was conducted in the seated posture
with a wall-mounted electronically braked arm cycle
ergometer (Angio 2000; Lode BV, Groningen, the
Netherlands) at a target cadence of 60 rpm to an end
point of fatigue or symptom limitation as described previously.8 A progressive, multistage protocol designed to
elicit exhaustion or symptoms within 5–12 min was used
with constant work increments of 50–200 kpm, equivalent to 8.2–32.7 W, every 2–3 min, depending on pretest
estimated exercise capacity.11 12 After a brief clinical
evaluation, a 12-lead ECG was recorded at baseline,
every minute during and postexercise and continuously
at peak effort. Blood pressure was obtained manually at
baseline and every 2–3 min during and postexercise.
Exercise capacity in METs (multiples of resting metabolic rate) was determined from the duration of effort at
the peak exercise work rate using the standard relationship between oxygen uptake and cycle ergometer work
rate, with 1 MET equivalent to 3.5 mL/kg/min and exercise METs=((2×kpm)+300)/(weight (kg)×3.5)).8 13 Peak
heart rate and heart rate recovery 1 min postexercise
were calculated from the ECG. One minute heart rate
recovery in beats/min was determined as the difference
between peak heart rate and the heart rate 1 min postexercise.5 Standard criteria were used for interpretation of
the exercise ECG with an abnormal tracing deﬁned as
≥1 mm of ST segment depression, measured 80 ms after
the J-point.11
2

Outcome events
Occurrence and date of death and MI, probable cause
of death, demographic, and clinical characteristics of
participants, medications prescribed, and coronary revascularisation procedures were ascertained by review of VA
electronic medical records preceding and following
stress testing until 5 November 2012 (10th anniversary of
the last participant stress test). This information was supplemented by examination of scanned reports of non-VA
episodes of care, telephone interviews of next of kin,
and data from death certiﬁcates, the Missouri
Department of Health and Senior Services, Social
Security Death Index and National Death Index.
Research staff were blinded to stress test ﬁndings at the
time of record review. The criteria for MI were elevated
creatine kinase-MB or troponin above the 99th centile
in the context of typical ECG ﬁndings or symptoms.
Censoring was not performed after MI or coronary
revascularisation.
Data analysis
Statistically signiﬁcant differences between group means
were determined with t tests. χ2 Analyses were used to
examine associations of categorical variables with mortality. Missing data were not imputed and analyses included
only existing values. Differences were considered signiﬁcant at p <0.05. Arm exercise variables identiﬁed in univariate analyses to be predictive of 5-year and 12-year
all-cause and cardiovascular mortality and 5-year cardiovascular mortality or MI were incorporated into multivariate Cox proportional hazards models. After removal
of non-signiﬁcant variables from these models, scores to
predict outcomes were then developed using remaining
arm exercise variables in the respective multivariate
models.1 2 Complete arm exercise data were available in
331 participants and arm exercise scores were developed
from this cohort. Weights were assigned to each independently predictive exercise variable, based on their
effect size coefﬁcient for a given outcome model.1 2
Relationships of scores and signiﬁcant demographic and
clinical variables with the various outcomes were also
evaluated with univariate and multivariate Cox proportional hazards models. C-statistics were used to evaluate
model discrimination of arm exercise scores before and
after adjustment for signiﬁcant demographic and clinical
variables and to compare the predictive value of arm
exercise scores with our recently published pharmacological MPI results.7 Kaplan-Meier curves were generated
to compare rates of survival or MI among patient
groups. Score cut points were selected to categorise
patients into high and low-risk groups, based on sequential step-wise comparisons of adjacent Kaplan-Meier
curve deciles beginning with the worst and most favourable outcome extremes, based on survival probability.
The log rank test for survival analysis was employed to
assess differences in Kaplan-Meier curve deciles. The
logistic growth model with the smallest sum of squares
was used to estimate relationships between arm exercise
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scores and survival. All analyses were performed with
SAS V. 9.4.14
RESULTS
Outcome events
There were 256 deaths (57.8%) over mean (SD) and
median (IQR) follow-up intervals of 12.0 (1.3) and 11.5
(10.8, 13.1) years, respectively, for survivors and 8.2 (3.4)
and 9.5 (4.3, 11.4) years, respectively, for the entire
cohort. Of 252 participants for whom probable cause of
death could be ascertained (98.4%), 102 were attributed
to a cardiovascular aetiology (40.4%). During follow-up,
70 participants (15.8%) experienced MI, 39 underwent
coronary artery bypass graft surgery (8.8%) and 78 had
percutaneous coronary interventions (17.6%).
Patient characteristics
Demographic and clinical characteristics of this population and their univariate associations with all-cause and
cardiovascular mortality at 5 and 12 years are shown in
table 1.
Resting ECG abnormalities that may preclude reliable
interpretation of the stress ECG included left bundle
branch block (2.0%), ST segment abnormalities ≥1 mm
(7.2%), and a ventricular paced rhythm (1.6%) but an
abnormal resting ECG was not associated with mortality
by multivariate analysis.
Similarly, although cardiovascular medications were
prescribed for a high proportion of patients in this
cohort, none were related to mortality after adjustment
for covariates. These medications included β adrenergic
blocking agents (40.6%), an ACE inhibitor, receptor
blocker or hydralazine (52.8%), statin (36.6%), platelet
antagonist (57.1%) and aldosterone antagonist (3.8%).
Arm exercise results
Arm exercise ﬁndings with univariate signiﬁcance are
shown in table 1 above and multivariate analyses of signiﬁcant univariate arm exercise results reported in tables
2 and 3 below. Arm exercise capacity in METs, 1 min
heart rate recovery and ST segment depression ≥1 mm
were the only exercise variables independently associated
with death or MI by multivariate analysis. For arm exercise capacity, the multivariate inverse relationship with
12-year all-cause mortality, expressed per SD of METs, was
HR 0.57, 95% CI 0.46 to 0.67; p<0.001 while the corresponding relationship with 12-year cardiovascular death
was HR 0.51, 95% CI 0.38 to 0.68; p<0.001. For 1 min
heart rate recovery, the multivariate inverse relationship
with 12-year all-cause mortality, expressed per SD of heart
rate recovery, was HR 0.66, 95% CI 0.55 to 0.79; p<0.001
and for 12-year cardiovascular death was HR 0.60, 95% CI
0.45 to 0.82;p<0.01. Arm exercise-induced ST segment
depression ≥1 mm was directly associated with outcome
end points as shown in tables 2 and 3.
Neither limiting nor non-limiting angina predicted
death ( p>0.05 by multivariate analysis). Exercise-induced

ventricular dysrhythmias were related to mortality by
univariate analysis ( p<0.01) but not after adjustment for
covariates. Coronary revascularisation by either coronary
artery bypass graft surgery or percutaneous coronary
intervention was associated with lower mortality (HR
0.52, 95% CI 0.38 to 0.72; p<0.001). However, there was
no interaction between coronary revascularisation and
the inverse relationship of arm exercise capacity and
heart rate recovery with death. Arm exercise-induced ST
segment depression was predictive of coronary revascularisation at 5 and 12 years (HR 2.29, 95% CI 1.25 to 4.19;
p=0.007 and HR 2.42, 95% CI 1.55 to 3.77; p<0.001,
respectively). Limiting angina also was associated with
coronary revascularisation at 5 and 12 years (HR 7.12,
95% CI 2.14 to 23.7; p=0.001 and HR 4.75, 95% CI 1.46
to 15.42; p<0.001, respectively).
Although β-adrenergic blocking agents were withheld
on the morning of testing, their use was still associated
with lower resting heart rate (70 (13) vs 78 (15) bpm),
peak heart rate (115 (23) vs 130 (20) bpm) and δ ( peak
—resting) heart rate (45 (31) vs 52 (20) bpm) (all
p<0.01) but did not affect arm exercise capacity in
METs, heart rate recovery or ST segment depression. In
addition, multivariate Cox proportional hazards analyses
revealed no signiﬁcant interaction between treatment
with β blockade and prediction of mortality with arm
exercise capacity in METs, 1 min heart rate recovery, and
ST segment depression, the components of the arm
exercise score.
Arm exercise scores
For arm exercise variables, data were available for the
following number and percentage of participants: METs
(n=440; 99.3%), peak heart rate (n=443; 100%), peak
systolic blood pressure (n=433; 97.5%), 1 min heart rate
recovery (n=340; 76.7%), angina (n=443; 100%), ventricular dysrhythmias (n=443; 100%) and an interpretable ST segment response (n=427; 96.4%). Arm exercise
scores were developed from complete data in 331 participants. Multivariate HRs and 95% CIs for arm exercise
scores and signiﬁcant univariate demographic and clinical associations with the respective outcomes in Cox
proportional hazards models are shown in table 4.
In ﬁgure 1, Kaplan-Meier curves for high and low-risk
groups, based on the displayed arm exercise score cut
points, are depicted for 5-year all-cause death (A), 5-year
cardiovascular death (B), 12-year all-cause death (C)
and 12-year cardiovascular death (D). Arm exercise
scores and C-statistic values for prediction of outcome
events before and after adjustment for signiﬁcant demographic and clinical covariates are presented in table 5.
To permit estimation of survival rates of individual
patients with a given arm exercise score, continuous relationships between corresponding arm exercise scores
and all-cause and cardiovascular survival over 5 and
12 years are shown in ﬁgure 2. For comparison with
pharmacological myocardial perfusion imaging (MPI)
results obtained in a separate cohort of 1730 patients
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Demographics
Age (years) (SD)

62.4 (10.6)
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Height (inches) (SD)

69.7 (2.9)

Weight (lbs) (SD)

218.1 (54.4)

Body mass index (kg/m2) (SD)

31.5 (7.1)

Race (black) (%)

79 (24.8)

Gender (women) (%)

8 (2.5)

Medications
β-blocker (%)

125 (38.7)

ACEI/ARB/hydralazine (%)

168 (52.0)

Statin (%)

124 (38.4)

Platelet antagonist (%)

190 (58.8)

Aldosterone blocker (%)

13 (4.0)

Resting vital signs
Heart rate (bpm) (SD)

74 (14)

Systolic BP (mm Hg) (SD)

136 (21)

Diastolic BP (mm Hg) (SD)

83 (12)

CV mortality
(n=50, 11.3%)

12-year
Survivors
(n=187, 42.2%)

68.6 (10.9)
p<0.001
69.4 (4.0)
p=0.36
196.3 (52.3)
p<0.001
28.7 (7.5)
p<0.001
33 (27.7)
p=0.54
1 (0.8)
p=0.28

68.3 (10.6)
p<0.001
68.5 (5.2)
p=0.01
191.8 (44.9)
p=0.001
29.1 (8.3)
p=0.03
10 (20.4)
p=0.50
1 (2.0)
p=0.84

59.7 (9.9)

55 (45.8)
p=0.17
66 (55.0)
p=0.58
40 (33.3)
p=0.33
63 (52.5)
p=0.23
4 (3.3)
p=0.74

30 (60.0)
p=0.005
31 (62.0)
p=0.19
18 (36.0)
p=0.75
28 (56.0)
p=0.71
0 (0.0)
p=0.15

75 (40.1)

78 (16)
p=0.01
132 (23)
p=0.07
78 (12)
p<0.001

77 (17)
p=0.13
132 (22)
p=0.23
79 (13)
p=0.03

74 (14)

69.9 (2.7)
223.2 (53.0)
32.1 (7.1)
48 (26.2)
5 (2.7)

91 (48.7)
74 (39.6)
100 (53.5)
6 (3.2)

135 (20)
84 (12)

All-cause mortality
(n=256, 57.8%)

CV mortality
(n=102, 23.0%)

67.3 (10.7)
p<0.001
69.4 (3.6)
p=0.17
204.2 (54.6)
p<0.001
29.7 (7.3)
p<0.001
64 (25.2)
p=0.81
4 (1.6)
p=0.41

65.9 (11.6)
p<0.001
69.1 (4.4)
p=0.08
205.6 (60.3)
p=0.01
30.3 (8.6)
p=0.06
24 (24)
p=0.68
3 (2.9)
p=0.89

105 (41.0)
p=0.85
143 (55.9)
p=0.13
90 (35.2)
p=0.34
153 (59.8)
p=0.19
11 (4.3)
p=0.56

47 (46.1)
p=0.33
63 (61.8)
p=0.03
36 (35.3)
p=0.47
60 (58.8)
p=0.38
1 (1.0)
p=0.24

76 (16)
p=0.20
135 (22)
p=0.80
80 (13)
p<0.001

75 (15)
p=0.55
135 (23)
p=0.97
80 (13)
p=0.01

Resting ECG results
Abnormal (%)

122 (37.8)

60 (50.0)
p=0.02

27 (54.0)
p=0.03

60 (32.1)

122 (47.7)
p=0.001

48 (47.1)
p=0.01

Clinical diagnoses
Hypertension (%)

243 (75.2)

96 (80.0)
p=0.29

39 (78.0)
p=0.67

141 (75.4)

198 (77.3)
p=0.63

80 (78.4)
p=0.56
Continued
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Arm exercise stress test (N=443)
5-year
Survivors
All-cause mortality
(n=323, 72.9%)
(n=120, 27.1%)
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Table 1 Association of demographic, medication, resting vital sign and ECG variables, clinical diagnoses and arm exercise responses with all-cause and cardiovascular
mortality over 5 and 12 years

Variable

Arm exercise stress test (N=443)
5-year
Survivors
All-cause mortality
(n=323, 72.9%)
(n=120, 27.1%)

Dyslipidaemia (%)

147 (45.5)

Current smoker (%)

100 (31.0)

Past smoker (%)

120 (37.2)

Diabetes (%)

111 (34.4)

CAD (%)

126 (39.0)

History of MI (%)

87 (26.9)

History of CHF (%)

29 (9.0)

Status post CABG (%)

53 (16.4)

Status post PCI (%)

43 (13.3)

Atrial fibrillation (%)

15 (4.5)

PAD (%)

75 (23.2)

COPD (%)

54 (16.7)

Renal disease (%)

19 (5.9)

Cancer (%)

20 (6.2)

125 (21)

Systolic BP (mm Hg) (SD)

172 (28)

Diastolic BP (mm Hg) (SD)

94 (15)

δ Values (Peak–Rest)
Heart rate (bpm) (SD)

52 (19)

46 (38.3)
p=0.18
44 (36.7)
p=0.25
43 (35.8)
p=0.80
50 (41.7)
p=0.16
56 (46.7)
p=0.15
50 (41.7)
p=0.003
28 (23.3)
p<0.001
29 (24.2)
p=0.06
16 (13.3)
p=1.00
27 (22.5)
p<0.001
55 (45.8)
p<0.001
48 (40.0)
p<0.001
18 (15.0)
p=0.002
26 (21.7)
p<0.001

21 (42.0)
p=0.64
20 (40.0)
p=0.20
17 (34.0)
p=0.67
20 (40.0)
p=0.44
29 (58.0)
p=0.01
23 (46.0)
p=0.006
17 (34.0)
p<0.001
17 (34.0)
p=0.003
11 (22.0)
p=0.10
14 (28.0)
p<0.001
27 (54.0)
p<0.001
20 (40.0)
p<0.001
8 (16.0)
p=0.01
7 (14.0)
p=0.04

117 (25)
p<0.001
161 (33)
p<0.001
90 (17)
p=0.01

115 (26)
p=0.002
164 (34)
p=0.08
91 (17)
p=0.28

39 (20)
p<0.001

38 (19)
p<0.001

12-year
Survivors
(n=187, 42.2%)
93 (49.7)
54 (28.9)
69 (36.9)
58 (31.0)
69 (36.9)
49 (26.2)
11 (5.9)
27 (14.4)
24 (12.8)
8 (4.3)
33 (17.7)
25 (13.4)
9 (4.8)
5 (2.7)

129 (20)
172 (28)
95 (15)

56 (19)

5

All-cause mortality
(n=256, 57.8%)

CV mortality
(n=102, 23.0%)

100 (39.1)
p=0.03
90 (35.2)
p=0.16
94 (36.7)
p=0.97
103 (40.3)
p=0.05
113 (44.1)
p=0.13
88 (34.4)
p=0.07
46 (18.0)
p<0.001
55 (21.5)
p=0.06
35 (13.7)
p=0.80
34 (13.3)
p=0.001
97 (37.9)
p<0.001
77 (30.1)
p<0.001
28 (10.9)
p=0.02
41 (16.0)
p<0.001

42 (41.2)
p=0.16
39 (38.2)
p=0.10
33 (32.4)
p=0.44
39 (38.2)
p=0.21
51 (50.0)
p=0.03
33 (32.4)
p=0.27
24 (23.5)
p<0.001
29 (28.4)
p=0.004
20 (19.6)
p=0.13
16 (15.7)
p<0.001
44 (43.1)
p<0.001
30 (29.4)
p<0.001
10 (9.8)
p=0.10
10 (9.8)
p=0.009

119 (23)
p<0.001
166 (31)
p=0.05
91 (16)
p=0.02

117 (22)
p<0.001
168 (31)
p=0.29
92 (16)
p=0.24

43 (20)
p<0.001

42 (18)
p<0.001
Continued

Special populations

Arm exercises responses
Peak values
Heart rate (bpm) (SD)

CV mortality
(n=50, 11.3%)

Downloaded from http://openheart.bmj.com/ on February 10, 2016 - Published by group.bmj.com

Xie Y, Xian H, Chandiramani P, et al. Open Heart 2016;3:e000333. doi:10.1136/openhrt-2015-000333

Table 1 Continued

Open Heart

6
Variable

Arm exercise stress test (N=443)
5-year
Survivors
All-cause mortality
(n=323, 72.9%)
(n=120, 27.1%)
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Systolic BP (mm Hg) (SD)

36 (24)

Diastolic BP (mm Hg) (SD)

11 (12)

Heart rate recovery (bpm)
1 min post (SD)

19 (10)

Exercise capacity (METs)

3.3 (0.9)

Angina
Limiting (%)

7 (2)

Non-limiting (%)

17 (6)

ST depression ≥1 mm (%)

39 (13)

Ventricular dysrhythmias (%)

26 (8)

CV mortality
(n=50, 11.3%)

12-year
Survivors
(n=187, 42.2%)

29 (23)
p=0.008
12 (12)
p=0.64

32 (20)
p=0.31
13 (11)
p=0.54

37 (23)

11 (8)
p<0.001
2.6 (0.8)
p<0.001

10 (7)
p<0.001
2.6 (0.8)
p<0.001

20 (9)

2 (2)
p=0.74
11 (10)
p=0.25
23 (20)
p=0.05
17 (14)
p=0.05

2 (4)
p=0.43
8 (16)
p=0.03
12 (26)
p=0.02
11 (22)
p=0.002

3 (2)

11 (14)

3.5 (0.9)

9 (5)
19 (10)
8 (4)

All-cause mortality
(n=256, 57.8%)

CV mortality
(n=102, 23.0%)

32 (24)
p=0.03
12 (11)
p=0.45

34 (22)
p=0.22
13 (12)
p=0.38

14 (9)
p<0.001
2.8 (0.9)
p<0.001

14 (9)
p<0.001
2.8 (0.9)
p<0.001

6 (2)
p=0.59
19 (8)
p=0.59
43 (18)
p=0.03
35 (14)
p=0.001

2 (2)
p=0.82
11 (11)
p=0.17
21 (21)
p=0.01
16 (16)
p<0.001

Data shown are means (SD) or n (%).
Statistically significant differences are designated in bold.
ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic
obstructive pulmonary disease; CV, cardiovascular; METs, resting metabolic equivalents; MI, myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention.
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Table 1 Continued

5-year all-cause
mortality
Peak heart rate (bpm)
Peak systolic blood pressure (mm Hg)
Peak diastolic blood pressure (mm Hg)
δ Heart rate (bpm)
δ Systolic blood pressure (mm Hg)
Heart rate recovery (bpm)
Exercise capacity (METs)
Non-limiting Angina
ST depression ≥1 mm
Ventricular dysrhythmias

1.00 (0.99 to 1.02)
0.99 (0.97 to 1.00)
1.01 (0.99 to 1.02)
1.01 (0.97 to 1.03)
1.01 (0.99 to 1.02)
0.93*** (0.90 to 0.96)
0.44*** (0.30 to 0.65)
1.85* (1.00 to 3.43)

5-year CV mortality

5-year CV mortality
or MI

12-year all-cause
mortality

1.00 (0.98 to 1.02)

1.00 (0.98 to 1.02)

0.99 (0.95 to 1.02)

1.00 (0.97 to 1.03)

0.99 (0.97 to 1.02)

0.92** (0.86 to 0.97)
0.55* (0.32 to 0.95)
1.60 (0.34 to 7.51)
2.59* (1.00 to 6.71)
2.08 (0.88 to 4.96)

0.93** (0.89 to 0.98)
0.51** (0.32 to 0.81)

1.00 (0.99 to 1.01)
1.00 (0.99 to 1.01)
0.99 (0.98 to 1.01)
1.00 (0.99 to 1.02)
1.00 (0.99 to 1.01)
0.96*** (0.94 to 0.98)
0.55*** (0.43 to 0.70)

3.07** (1.44 to 6.57)
1.90 (0.90 to 4.02)

1.70* (1.10 to 2.61)
1.47 (0.94 to 2.31)

2.48** (1.34 to 4.59)
1.38 (0.69 to 2.79)

12-year CV mortality
1.00 (0.98 to 1.01)

0.96* (0.92 to 1.00)
0.55*** (0.38 to 0.79)

HRs for continuous variables indicate hazard change per single integer measurement unit.
Statistically significant differences are designated in bold.
*p<0.05; **p<0.01; ***p<0.001 by multivariate analysis.
CV, cardiovascular; METs, resting metabolic equivalents; MI, myocardial infarction.

Table 3 Multivariate parameter estimates, HRs and 95% CIs for arm exercise variables based on step-wise Cox analysis
5-year CV mortality
Parameter
estimate
HR

5-year CV mortality or MI
Parameter
estimate
HR

12-year all-cause
mortality
Parameter
estimate
HR

12-year CV mortality
Parameter
estimate
HR

−0.06

−0.10

−0.08

−0.04

−0.05

−0.78
0.76

0.94***
(0.91 to 0.97)
0.46 ***
(0.33 to 0.63)
2.14**
(1.22 to 3.78)

−0.75
1.07

0.90***
(0.86 to 0.95)
0.47**
(0.29 to 0.77)
2.92**
(1.33 to 6.41)

HRs for continuous variables indicate hazard change per single integer measurement unit.
*p<0.05; **p<0.01; ***p<0.001 by multivariate analysis.
CV, cardiovascular; METs, resting metabolic equivalents; MI, myocardial infarction.

−0.73
1.22

0.93***
(0.89 to 0.96)
0.48***
(0.32 to 0.73)
3.38***
(1.70 to 6.70)

−0.63
0.61

0.96***
(0.94 to 0.98)
0.54***
(0.44 to 0.65)
1.85**
(1.24 to 2.76)

−0.72
0.90

0.95**
(0.92 to 0.98)
0.49***
(0.36 to 0.67)
2.46**
(1.37 to 4.42)

7
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Heart rate recovery
(bpm)
Exercise capacity
(METs)
ST depression ≥1 mm

5-year all-cause mortality
Parameter
estimate
HR
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Arm exercise score
Demographics
Age (years)
Body mass index (kg/m2)
Medications
β-blocker
ACEI/ARB/hydralazine
Resting vital signs
Heart rate (bpm)
Diastolic BP (mm Hg)
Resting ECG results
Abnormal
Clinical diagnoses
Dyslipidaemia
Diabetes
CAD
History of MI
History of CHF
Status post CABG
Atrial fibrillation
PAD
COPD
Renal disease
Cancer

Outcome
5-year all-cause mortality

5-year CV mortality

5-year CV mortality or MI

12-year all-cause mortality

12-year CV mortality

0.96*** (0.94 to 0.98)

0.92*** (0.88 to 0.96)

0.95*** (0.92 to 0.97)

0.96*** (0.95 to 0.98)

0.96*** (0.94 to 0.98)

1.01 (0.99 to 1.04)
0.96* (0.92 to 0.99)

0.99 (0.96 to 1.03)
0.98 (0.93 to 1.04)

1.01 (0.98 to 1.04)

1.02 (1.00 to 1.03)
0.97** (0.95 to 0.99)

1.01 (0.99 to 1.04)
0.99 (0.96 to 1.02)

0.92 (0.43 to 1.96)
1.43 (0.87 to 2.34)
1.02 (1.00 to 1.03)
0.98* (0.96 to 1.00)

1.00 (0.97 to 1.03)

1.03 (0.63 to 1.70)

0.54 (0.25 to 1.14)

0.73 (0.40 to 1.36)

0.99* (0.97 to 1.00)

1.00 (0.98 to 1.02)

1.18 (0.86 to 1.61)

0.93 (0.56 to 1.55)

0.67** (0.49 to 0.90)
0.91 (0.66 to 1.26)
1.29 (0.81 to 2.05)
1.17 (0.64 to 2.13)
3.50*** (1.92 to 6.38)
1.75* (1.07 to 2.84)
1.19 (0.73 to 1.95)
1.82 (0.87 to 3.81)
2.41** (1.28 to 4.55)

1.40 (0.57 to 3.46)
1.24 (0.55 to 2.78)
1.61 (0.67 to 3.86)
1.71 (0.71 to 4.10)
6.83*** (2.77 to 16.88)
1.73 (0.75 to 3.94)
1.06 (0.47 to 2.37)
2.61 (0.98 to 6.94)
1.64 (0.44 to 6.08)

0.97 (0.53 to 1.77)
1.46 (0.79 to 2.68)
1.96 (1.00 to 3.84)
1.22 (0.61 to 2.43)
4.31*** (2.03 to 9.16)
2.44** (1.29 to 4.61)
1.12 (0.60 to 2.09)
1.74 (0.75 to 4.05)

1.43 (0.94 to 2.19)
2.09** (1.28 to 3.39)
1.74** (1.24 to 2.43)
1.26 (0.91 to 1.77)
1.30 (0.75 to 2.24)
2.17** (1.35 to 3.49)

1.63 (0.84 to 3.16)
1.53 (0.81 to 2.89)
3.27** (1.47 to 7.25)
2.04** (1.19 to 3.47)
1.41 (0.81 to 2.45)
1.07 (0.36 to 3.17)

HRs for continuous variables indicate hazard change per single integer measurement unit.
Statistically significant differences are designated in bold.
*p<0.05; **p<0.01; ***p<0.001 by multivariate survival analysis.
ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CAD, coronary artery disease; CHF, congestive heart failure; CABG, coronary artery bypass grafting; COPD, chronic
obstructive pulmonary disease; CV, cardiovascular; MI, myocardial infarction; PAD, peripheral arterial disease.
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Figure 1 Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D,
respectively) with number of participants at risk and 95% CIs stratified by cut points into high and low-risk groups based on arm
exercise scores.

evaluated over the same 1997–2002 time interval,7
receiver operator curve plots of arm exercise scores, best
ﬁt models of signiﬁcant pharmacologic MPI study 5-year
and 12-year mortality predictors ( perfusion defect
number, type, and size and the change in heart rate
from baseline to peak stress as described recently7), and
an abnormal versus normal pharmacological MPI result,
are depicted in ﬁgure 3.

DISCUSSION
For the ≥50% of patients unable to perform treadmill
or other leg exercise, we have developed a scoring
system for prediction of all-cause and cardiovascular

mortality over 5 and 12 years and cardiovascular mortality or MI over 5 years using easily obtainable information
from arm exercise ECG stress testing. No other scoring
system and few prognostic data are currently available
for arm exercise testing. However, we have recently
observed that arm exercise is an equivalent or superior
alternative to pharmacological MPI for many patients
who are unable to perform lower extremity exercise.7 As
illustrated in ﬁgure 3, this is further emphasised by the
higher area under the curve of C-statistic plots for prediction of mortality with arm exercise ECG stress test
scores than for pharmacological MPI results. Arm exercise also provides important functional and physiological
information on exercise capacity, heart rate recovery and

Table 5 Arm exercise scores with C statistic values before and after adjustment for significant demographic and clinical
predictors
Outcome

Score equation

Area under the curve (AUC)*
Unadjusted
Adjusted†

5-year-all-cause mortality
5-year-CV mortality
5-year-CV mortality or MI
12-year-all-cause mortality
12-year-CV mortality

HRR+13.0×METs−12.6×STΔ (0/1)
HRR+7.3×METs−10.5×STΔ (0/1)
HRR+9.4×METs−15.7×STΔ (0/1)
HRR+14.5×METs−14.2×STΔ (0/1)
HRR+13.8×METs−17.1×STΔ (0/1)

0.77
0.81
0.79
0.77
0.78

0.86
0.88
0.83
0.83
0.82

*C-statistic (AUC) based on a logistic model.
†Arm Exercise Score adjusted for significant demographic and clinical variables indicated in table 4.
AUC, area under the curve; CV, cardiovascular; HRR, heart rate recovery at 1 min postexercise; METs, resting metabolic equivalents; MI,
myocardial infarction; ST, ST segment depression.
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Figure 2 The continuous curvilinear relationship between arm exercise scores and 5-year and 12-year all-cause (A and C,
respectively) and cardiovascular survival (B and D, respectively) with associated scatter plots. HRR, heart rate recovery at 1-min
postexercise; METs, arm exercise capacity in resting metabolic equivalents; STΔ, ST segment depression either <1 mm (0) or
≥1 mm (1).

clinical symptoms relevant to patient management decisions such as referral for cardiac catheterisation. This
information is not available with pharmacological MPI
or echocardiographic evaluations. Although arm and leg
exercise ECG stress tests are less sensitive for detection
of cardiac ischaemia than MPI,7 10 11 we have demonstrated a close relationship between an abnormal arm
exercise ECG result and the size and reversibility of perfusion defects.10 15 Arm exercise ECG testing does not
require exposure to ionising radiation and is several
times less expensive and time consuming for patients
and staff than pharmacological imaging. Institutional
resource and space requirements are also much less for
arm exercise ECG testing than for treadmill or pharmacological imaging evaluations.
We observed a C-statistic of 0.81 for prediction of cardiovascular mortality over 5 years with arm exercise,
which is similar to C-statistic results of 0.85 and 0.75 in
outpatients and inpatients, respectively, for prognostication of cardiovascular mortality over 4–5 years with the
Duke Treadmill Score.1 2 However, despite the ability of
arm exercise and Duke Treadmill Score C-statistics to discriminate outcome events, there are notable differences
between our cohort and that from which the Duke
10

Treadmill Score was derived. Our cohort is comprised of
a very high-risk veteran population with a 5-year cardiovascular mortality of about 11% in comparison with the
3–4% 4-year cardiovascular mortality for outpatients and
8% mortality for inpatients in the Duke sample.1 2 The
high mortality of our population is typical of patients
unable to perform treadmill exercise.4 Our cohort
included inpatients and outpatients, was about 10–
15 years older, and was comprised of 98% men versus
67–70% men in the Duke database.1 2 The prevalence
of peripheral arterial disease, congestive heart failure
and atrial ﬁbrillation in our population was 29%, 13%,
and 10%, respectively, all of which were associated with
worsened cardiovascular mortality. The greater relative
prognostic value of clinical predictors in our population
versus the cohort used to derive the Duke Treadmill
Score2 may reﬂect the much higher outcome event rate
in our group. However, functional assessment and estimation of prognosis in these high-risk patients is likely
to be easier with arm exercise scores than with more
complex models of clinical variables, despite their comparable C-statistic values.
In contrast to the Duke Treadmill Score, which stratiﬁed patients into high, low and intermediate-risk
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Figure 3 Receiver operator curve plots for prognostication of 5-year and 12-year all-cause (A and C, respectively) and
cardiovascular mortality (B and D, respectively) with arm exercise scores (Arm Score AUC), best fit model pharmacological
myocardial perfusion imaging (MPI) study predictors ( perfusion defect number, type and size and the change in heart rate from
rest to peak stress;7 Best fit pharm MPI AUC), and an abnormal versus normal pharmacological MPI result (Abn pharm MPI
AUC), for 1730 pharmacological evaluations performed during the same 1997–2002 time interval. AUC, area under the curve.

groups,2 best ﬁt statistical models of our arm exercise
cohort identiﬁed only very high and relatively low-risk
groups. The difference in 5-year cardiovascular mortality
between the higher and lower risk groups in our cohort
(29% vs 3%) was similar to the Duke sample over 4–
5 years (28% vs 1–2%).2 However, we did not identify an
intermediate risk group, which comprised about half of
the Duke sample,2 and the proportion of patients in the
high-risk group of our cohort was much greater than in
the Duke cohort (39% vs 8%).2 This difference is likely
related to the very high-risk nature of our population,
which experienced a 5-year all-cause mortality rate of
23%. Rates of all-cause and cardiovascular survival in
our cohort may be estimated over a continuum of arm
exercise scores based on curvilinear relationships shown
in ﬁgure 2.
Our arm ergometer score and the Duke Treadmill
Score are comprised of three test variables that include
exercise capacity and stress-induced ST segment depression data.2 However, there are other important differences in the individual components. First, the Duke
Treadmill Score does not include heart rate recovery,
which is an element of our arm exercise score, but was
not found to be strongly associated with mortality until
several years after publication of the Duke results.2 5
Second, we did not observe an association of angina,

either limiting or non-limiting, with cardiovascular mortality, whereas this ﬁnding is a component of the Duke
Treadmill Score.2 One explanation for this is that unlike
the Duke investigators, we did not censor our results for
coronary revascularisation, which has become much
more common than during the 1969–1990 era when the
Duke data were obtained.1 2 We have previously observed
that arm exercise-induced angina was strongly associated
with subsequent coronary revascularisation,9 which also
predicted lower mortality in our population, possibly
mitigating the effect of angina as a prognosticator of
death. Thus, our data reﬂect actual clinical practice outcomes rather than the natural history of coronary artery
disease. In addition, certain classes of medications such
as statins and platelet antagonists, which also improve
cardiovascular mortality, were not widely prescribed
before 1990, and might inﬂuence the natural history of
patients with angina. However, there was no association
of medications with mortality in our cohort. Finally, in
contrast to the Duke Treadmill Score,2 we did not
observe a relationship between the magnitude of arm
exercise-induced ST segment depression and subsequent
cardiovascular mortality. This difference could be
explained by our smaller sample size or by the effects of
subsequent coronary revascularisation and/or medical
treatment on cardiovascular mortality of patients with a
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marked arm exercise-induced ST segment depression as
noted above for individuals with stress-induced angina.
In this context, we have also observed an association
between arm exercise-induced ST-segment depression
and coronary revascularisation.9
Arm exercise capacity in METs and heart rate recovery
exhibited robust inverse relationships with cardiovascular,
non-cardiovascular and all-cause mortality after adjustment for covariates and there was no interaction of these
effects with coronary revascularisation. These results are
similar to ﬁndings with treadmill or leg cycle ergometer
testing, for which several investigators have reported
powerful inverse relationships between exercise capacity
and/or heart rate recovery and long term all-cause and
cardiovascular mortality in lower risk populations.5 12 16–
18
Our arm exercise score and pharmacological MPI
results are also consistent with other studies demonstrating that leg exercise capacity is a better predictor of mortality than stress nuclear perfusion imaging results.18 19
There are important differences in cardiovascular
responses to arm and leg exercise, however. In young
healthy participants, peak oxygen uptake with arm exercise averaged 56% of treadmill maximal oxygen uptake.8
Peak heart rate was 5–8% lower for arm versus leg work
whereas systolic blood pressure is greater for arm exercise.8 20 Thus, the rate-pressure product and cardiac
work requirement are comparable for the two exercise
modalities, despite the lower peak oxygen uptake during
arm exercise.
Since our study was initiated in 1997, new imaging
modalities such as coronary CT angiography have
emerged21 and the number of patients unable to
perform treadmill exercise continues to increase.4 These
new imaging modalities provide potentially useful information but, similar to MPI stress testing, require exposure to ionising radiation,21 22 contribute to rapidly
increasing healthcare costs,23 and fail to provide prognostic and functional information on exercise capacity,
symptomatic, cardiovascular and ECG responses to the
relevant physiological stress of exercise. Nephrotoxicity
also is a potential limitation of coronary CT angiography.
Arm exercise ECG stress testing is a potential solution to
these problems for many patients unable to perform leg
exercise.
Major limitations of this arm exercise scoring system
are that it is based on retrospective data and was developed in a high-risk cohort of veterans, possibly introducing selection bias. Deﬁnitive conﬁrmation of this
approach will require a randomised prospective clinical
trial of arm exercise versus pharmacologic stress testing,
which is being planned. Generalisability of these equations to younger, healthier populations or to women is
uncertain and also will require further investigation.
Arm exercise is not feasible for patients with upper
extremity disabilities and ECG testing alone may not be
adequate for patients with left bundle branch block or
other ECG abnormalities that interfere with accurate
interpretation of the stress ECG.
12

In conclusion, we have developed a simple arm exercise ECG scoring system for prediction of 5-year and
12-year all-cause and cardiovascular mortality and 5-year
cardiovascular mortality or MI. These arm exercise
scores have comparable accuracy to the Duke Treadmill
Score, are at least equivalent to pharmacological MPI
for this purpose, and are the only data available for
patients who cannot perform leg exercise. Thus,
greater clinical use of arm exercise ECG stress testing
in this population is a potentially equivalent or superior
alternative to non-selective pharmacological imaging for
cost-effective clinical decision making without radiation
exposure.
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